Vertex Ventures HC — Full Portfolio
10 tracked investments · listed companies and verified rows first
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)inKEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCCambridge Innovation CapitalLongwood FundSR One Capital ManagementSV Health Investors+2 more
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
Co-investorsLeaps by BayerRA Capital
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesBroadview VenturesLongitude CapitalAdams Street PartnersARCH Venture PartnersVertex Ventures
HealthtechFremont, US
Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)
BoardJoshua Makower(Director)Shahzad Malik(Director)in
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Gilde Healthcare
Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder.
BiotechHealthtechMedical DevicesSan Jose, US
Alexander Yeh(Founder)inMilton M. Morris(Executive Officer, Director)inDave Van Meter(Chief Executive Officer)Steve Paul(Chief Commercial Officer)in
Co-investorsCerity Partners VenturesForeground CapitalPortfoliaTreo Ventures, LlcWindham Capital PartnersAction Potential Venture Capital Ltd.
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)inTom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)inParameswaran Hari(Chief Medical Officer)inJulie Feder(Chief Financial Officer)inDana Alexander(Chief Technical Officer)in
Co-investorsAtlas VentureTCG Crossover
BiotechWaltham, US
James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)
BoardJens Eckstein(Director)
Co-investorsSR One Capital ManagementBioHealth Innovation, Inc.Pfizer VenturesTakeda Ventures
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalThird Rock Ventures
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibodies for cancer, including lead candidate TORL-1-23 targeting CLDN6 in ovarian cancer.
BiotechCulver City, US
Mark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)Amit Sinha(Director)Lynn Seely(Director)
Co-investorsOCV PartnersRA CapitalCowen Healthcare InvestmentsGoldman SachsPerceptive Xontogeny Venture
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BlackThorn Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.